Technical Analysis for RLAY - Relay Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 38.235 1.04% 0.40
RLAY closed up 3.42 percent on Wednesday, August 5, 2020, on 44 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Up
Historical RLAY trend table...

Date Alert Name Type % Chg
Inside Day Range Contraction 4.50%
Up 3 Days in a Row Strength 4.32%
Up 4 Days in a Row Strength 4.32%
Up 3 Days in a Row Strength 7.83%
Outside Day Range Expansion 9.24%
NR7 Range Contraction 11.15%
NR7-2 Range Contraction 11.15%
Hot IPO Pullback Bullish Swing Setup 12.85%
NR7 Range Contraction 12.85%
NR7-2 Range Contraction 12.85%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its product candidates include RLY-1971, an oral small molecule inhibitor of the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 (SHP2) that is in Phase 1 dose escalation studies in patients with advanced or metastatic solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2) for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Drug Discovery Tyrosine Kinase Receptors Enzymes Advanced Solid Tumors Tyrosine Kinase C Met Fibroblast Growth Factor Receptor 2 Metastatic Solid Tumors

Is RLAY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 49.89
52 Week Low 33.19
Average Volume 587,596
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 0.00
10-Day Moving Average 35.38
Average True Range 4.23
ADX 0.0
+DI 32.50
-DI 12.74
Chandelier Exit (Long, 3 ATRs ) 37.19
Chandelier Exit (Short, 3 ATRs ) 45.89
Upper Bollinger Band 0.00
Lower Bollinger Band 0.00
Percent B (%b) 0.0
BandWidth 0.00
MACD Line -0.08
MACD Signal Line -0.08
MACD Histogram -0.0028
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 43.89
Resistance 3 (R3) 43.84 41.79 42.88
Resistance 2 (R2) 41.79 40.25 41.81 42.54
Resistance 1 (R1) 39.81 39.30 40.80 39.86 42.21
Pivot Point 37.76 37.76 38.25 37.78 37.76
Support 1 (S1) 35.78 36.22 36.77 35.83 33.47
Support 2 (S2) 33.73 35.27 33.75 33.14
Support 3 (S3) 31.75 33.73 32.80
Support 4 (S4) 31.80